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vided the original work is properly cited.†These authors contributed equally to this publication.Many conditions culminate in heart failure (HF), a multi-organ systemic syndrome with an intrinsically poor prognosis.
Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the fore-
front of developments within the treatment of HF in the past. Indeed, multiple trials aimed to validate these agents in the 1980s
and early 1990s, resulting in a large and robust evidence-base supporting their use clinically. An established treatment paradigm
now exists for the treatment of HF with reduced ejection fraction (HFrEF), but there have been very few notable developments in
recent years. HF remains a signiﬁcant health concern with an increasing incidence as the population ages. We may indeed be
entering the surgical era for HF treatment, but these therapies remain expensive and inaccessible to many. Newer
pharmacotherapeutic agents are slowly emerging, many targeting alternative therapeutic pathways, but with mixed results.
Metabolic modulation and manipulation of the nitrate/nitrite/nitric oxide pathway have shown promise and could provide the
answers to ﬁll the therapeutic gap between medical interventions and surgery, but further deﬁnitive trials are warranted. We re-
view the signiﬁcant evidence base behind the current medical treatments for HFrEF, the physiology of metabolic impairment in
HF, and discuss two promising novel agents, perhexiline and nitrite.
Abbreviations
ANT, adenine nucleotide translocase; ARB, angiotensin receptor blocker; BEAUTIFUL, morBidity-mortality EvAlUaTion of
the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction trial; BNP, brain natriuretic
peptide; CHARM, Candesartan in Heart failure - Assessment of moRtality and Morbidity; CK, creatine kinase; COPERNI-
CUS, CarvedilOl ProspEctive RaNdomIzed CUmulative Survival Study; CPT, carnitine palmitoyltransferase; ESC, European
Society of Cardiology; FA, fatty acid; FADH2, ﬂavin adenine dinucleotide; HF, heart failure; HFpEF, heart failure and pre-
served ejection fraction; HFrEF, heart failure and reduced ejection fraction; ISDN, isosorbide dinitrate; LVEF, left ventricular
ejection fraction; MERIT-HF, MEtoprolol cr/xl Randomised Intervention Trial in congestive Heart Failure; NYHA, New York
Heart Association; PDH, pyruvate dehydrogenase; PCr, phosphocreatine; Pi, inorganic phosphate; PPP, pentose phosphate
pathway; RAAS, renin–angiotensin–aldosterone system; RCT, randomized controlled trial; SENIORS, Study of the Effects of
Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure; SHIFT, Systolic Heart failure
treatment with the If inhibitor ivabradine Trial; TCA, tricarboxylic acid; UCP, uncoupling protein; V-HeFT, vasodilator
heart failure trial
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Chronic heart failure (HF) is a complex, systemic, multi-organ
syndrome, which represents a common endpoint for many
cardiac conditions (Follath et al., 1998). Traditionally, it is
characterized by haemodynamic impairment and progressive
neurohormonal dysregulation, with increased sympathetic acti-
vation, elevated peripheral vascular resistance and cardiac
remodelling (Braunwald and Bristow, 2000). More recently,
metabolic impairment (Neubauer, 2007) and activation of
inﬂammatory responses (Rauchhaus et al., 2000) have been in-
creasingly recognized. At a population level, HF affects around
900 000 Britons, half of whom die within 5 years of diagnosis
(Hobbs et al., 2007). At current hospitalization rates, 70% of
which involve patients aged >65 years, HF costs the UK 2% of
the total annual National Health Service budget (Basu et al.,
2008), and this is set to increase further as the population ages.
Pharmacotherapeutic agents geared towards correcting
neurohormonal dysregulation have occupied the forefront
of developments within the treatment of HF in the past,
resulting in a large and robust evidence-base supporting their
use clinically. This evidence underpins the European Society
of Cardiology (ESC) Guidelines for the Diagnosis and Treat-
ment of Acute and Chronic Heart Failure, most recently
updated in 2012 (McMurray et al., 2012). The pace and
success of development of novel pharmacotherapeutic agents
over the last 20 years has been disappointing. However, new
agents are slowly emerging. LCZ696 (a combination therapy
of an angiotensin receptor blocker and a neprilysin inhibitor)1912 British Journal of Pharmacology (2016) 173 1911–1924demonstrated superiority over angiotensin converting
enzyme (ACE) inhibitors in 8399 patients with HF and
reduced ejection function (HFrEF), with a reduction in the
risk of all-cause mortality of 12.6% (95% CI 7–18%;
P < 0.0001) (Packer et al., 2015). Inﬂammatory mediators
such as the key cytokine TNF-α were also identiﬁed as targets
for novel therapies in patients with HF; however, human
trials have shown disappointing results (Chung et al., 2003;
Mann et al., 2004; Torre-Amione et al., 2008). Despite this, a
signiﬁcant advancement in our understanding of inﬂamma-
tion in HF has been made and has generated further research
in this ﬁeld (Heymans et al., 2009). Investigation into cardiac
myosin activators [such as omecamtiv mecarbil, which has
been shown to improve systolic function and is well tolerated
(Greenberg et al., 2015)], phosphodiesterase inhibition, ma-
nipulation of the nitrate/nitrite/NO pathway, metabolic
modulation, stem cell therapy and gene therapy is currently
underway (Shah and Mann, 2011; Tilemann et al., 2012).
Up to 50% of patients with HF have a preserved ejection
fraction of ≥50% (HFpEF). The therapeutic paradigm that
has been successful in HFrEF has failed in this syndrome
(Yusuf et al., 2003; Cleland et al., 2006; Massie et al., 2008; Pitt
et al., 2014). Therefore, effective therapies are urgently
needed. With the rapid advancements in the development
of implantable cardiac devices such as left ventricular assist
devices, we may be entering the surgical era of HF treatment.
These interventions, despite their clearly beneﬁcial use in pa-
tients awaiting cardiac transplantation or as an alternative
destination therapy, remain expensive and lead to device-
Pharmacotherapies in heart failure BJPrelated complications. As such, surgery is reserved for patients
with end-stage HF (Mancini and Colombo, 2015).
We suggest that targeting alternative pathways other than
those used by the well-established HFrEF pharmacological
agents will prove beneﬁcial in the advancement of pharmaco-
therapy in HF (Figure 1). Metabolic modulation has shown a
promising and favourable effect proﬁle in Phase 2 randomized
controlled trials (RCTs) performed by our group in patients with
HFrEF (Lee et al., 2005) and hypertrophic cardiomyopathy
(Abozguia et al., 2010). However, to date, there have been no
Phase 3 trials. A meta-analysis assessing the addition of
trimetazidine to conventional therapy in patients with HFrEF
demonstrated a reduction in hospitalization for cardiac causes
(RR: 0.43, P = 0.03) and improved symptomatology and param-
eters of cardiac functioning, but had no effect on all-cause
mortality (Zhang et al., 2012). Our group and others have also
investigated nitrite, which has been shown to be a hypoxic-
dependent vasodilator, signiﬁcantly improving cardiac haemo-
dynamics without causing symptomatic hypotension (Maher
et al., 2008). Nitrite has also been shown to exhibit additional
beneﬁts of metabolic modulation within skeletal muscle (Bailey
et al., 2009), which may translate to cardiac muscle. Herein, we
will review the signiﬁcant evidence base behind the current
medical treatments for HFrEF, the physiology of metabolic
impairment in HF and discuss two promising novel agents,
perhexiline and nitrite.ESC guidelines
The ESC guidelines recommend approved agents for use in HFrEF
based on robust clinical evidence (Table 1). Pharmacotherapeutic
agents with class I (strong evidence of beneﬁt) recommendationsFigure 1
Overview of compensatory mechanisms in HF and complementary pharmac
iological changes take place in HF. Multiple pharmacotherapeutic agents hav
den in HFrEF. ACE, angiotensin converting enzyme; AMI, acute myocardial
H2O, water; HDZ, hydralazine; HR, heart rate; HTN, hypertension; ISDN, iso
antagonists; Na, sodium; NP, neprilysin; RAAS, renin–angiotensin–aldosteroinclude β-blockers and ACE inhibitors [or angiotensin receptor
blockers (ARBs) when ACE inhibitors are not tolerated] for all
patients with HFrEF in the ﬁrst instance, regardless of symptom-
atology. Additional agents including hydralazine and isosorbide
dinitrate [in African-American patients with New York Heart As-
sociation (NYHA) class III–IV on an ACE inhibitor and β-blocker]
and mineralocorticoid receptor antagonists [NYHA class II–IV
with left ventricular ejection fraction (LVEF) ≤35%] are indicated
as necessitated by ongoing NYHA class II–IV symptoms. These
medications are supported by class A evidence (data from
multiple RCTs). Recommendations in favour of treatment being
beneﬁcial (class IIb) have also been made by the ESC for the use
of digoxin and ivabradine (if HR ≥70 bpm) in HFrEF with sinus
rhythm, unless contraindicated, to decrease hospitalizations
(McMurray et al., 2012).Evidence-based pharmacological
agents
ACE inhibitors
Diminishing sodium delivery and arterial pressure to the
renal glomeruli in patients with HF activates the
renin–angiotensin–aldosterone system (RAAS), which is
further augmented by sympathetic activation. This compen-
satory mechanism causes potent vasoconstriction (with an
increase in total peripheral resistance and therefore afterload)
and salt and water retention to increase circulatory volume
(Furberg and Yusuf, 1985). ACE is a common link between
the RAAS and kallikrein–kinin pathways, converting angio-
tensin I to the salt-retentive, vasoconstrictive and hypertro-
phic angiotensin II, and degrading the vasodilatory and salt-otherapeutic agents. Compensatorymechanisms and key pathophys-
e been developed to target these pathways and improve disease bur-
infarction; ARBs, angiotensin receptor blockers; CO, cardiac output;
sorbide dinitrate; LV, left ventricle; MRAs, mineralocorticoid receptor
ne system; ROS, reactive oxygen species; RV, right ventricle.
British Journal of Pharmacology (2016) 173 1911–1924 1913
Ta
b
le
1
Pi
vo
ta
lc
lin
ic
al
tr
ia
ls
fo
r
ph
ar
m
ac
ot
he
ra
pe
ut
ic
ag
en
ts
ap
pr
ov
ed
fo
r
th
e
tr
ea
tm
en
t
of
H
Fr
EF
H
Fr
EF
ag
en
t
Ex
am
p
le
R
el
ev
an
t
tr
ia
ls
N
u
m
b
er
o
f
p
a
ti
en
ts
R
el
a
ti
ve
ri
sk
R
ef
er
en
ce
A
ll
-c
a
u
se
m
o
rt
al
it
y
(9
5
%
C
I)
H
ea
rt
fa
il
u
re
h
o
sp
it
al
iz
at
io
n
s
(9
5
%
C
I)
A
n
gi
ot
en
si
n
co
nv
er
tin
g
en
zy
m
e
(A
C
E)
in
hi
b
it
or
s
En
al
ap
ri
l
C
O
N
SE
N
SU
S
tr
ia
l
22
89
0.
73
(0
.6
3–
0.
84
,P
<
0.
00
00
2)
0.
73
(N
/A
,P
=
0.
00
01
)
C
O
N
SE
N
SU
S
Tr
ia
lS
tu
d
y
G
ro
up
,1
9
87
SO
LV
D
tr
ia
l
25
69
0.
84
(0
.7
4–
0.
95
,P
=
0.
00
36
)
0.
74
(0
.6
6–
0.
72
,P
<
0.
00
01
)ǂ
Th
e
SO
LV
D
In
ve
st
ig
at
or
s,
19
92
C
ap
to
p
ri
l
SA
VE
tr
ia
l
22
31
0.
81
(0
.6
8–
0.
97
,P
=
0.
01
9)
0.
78
(0
.6
3–
0.
96
,P
=
0.
01
9)
Pf
ef
fe
r
et
al
.,
19
92
Ra
m
ip
ri
l
A
IR
E
tr
ia
l
20
06
0.
73
(0
.6
0–
0.
89
,P
=
0.
00
2)
N
/A
Th
e
A
IR
E
St
ud
y
G
ro
up
,1
99
3
A
n
gi
ot
en
si
n
re
ce
p
to
r
bl
oc
ke
rs
(A
RB
s)
C
an
d
es
ar
ta
n
C
H
A
RM
-a
lt
er
na
ti
ve
tr
ia
l
20
28
0·
80
(0
·6
6–
0·
96
,P
=
0.
02
)
0·
61
(0
·5
1–
0·
73
,P
<
0.
00
01
)
G
ra
n
ge
r
et
al
.,
20
03
Va
ls
ar
ta
n
Va
l-H
eF
T
tr
ia
l
(a
d
de
d
to
A
C
E-
Is
)
50
10
1.
02
(0
.8
8–
1.
1,
P
=
0.
80
)§
0.
87
(0
.7
7–
0.
97
,P
=
0.
00
9)
*,
ǂ
C
oh
n
an
d
To
go
no
ni
,2
00
1
VA
LI
A
N
T
tr
ia
l
(n
on
-in
fe
ri
or
it
y)
14
70
3
1.
00
(0
.9
0–
1.
11
,P
=
0.
98
)*
,¥
0.
97
(0
.9
0–
1.
05
,P
=
0.
51
)ǂ
,¥
Pf
ef
fe
r
et
al
.,
20
03
M
in
er
al
o
co
rt
ic
oi
d
re
ce
pt
or
an
ta
g
on
is
ts
Sp
ir
on
ol
ac
to
n
e
RA
LE
S
tr
ia
l
16
63
0.
70
(0
.6
0–
0.
82
,P
<
0.
00
1)
0.
65
(0
.5
4–
0.
77
,P
<
0.
00
1)
Pi
tt
et
al
.,
19
99
Ep
le
re
no
ne
EM
PH
A
SI
S-
H
F
tr
ia
l
27
37
0.
76
(0
.6
2–
0.
93
,P
=
0.
00
8)
0.
58
(0
.4
7–
0.
70
,P
<
0.
00
1)
Z
an
n
ad
et
al
.,
20
11
β-
Bl
oc
ke
rs
Bi
so
pr
ol
ol
C
IB
IS
-I
I
tr
ia
l
26
47
0.
66
(0
.5
4–
0.
81
,P
<
0.
00
01
)
0·
64
(0
·5
3–
0·
79
,P
=
0.
00
1)
C
IB
IS
-I
IS
tu
d
y
G
ro
up
,1
99
9
M
et
o
pr
ol
ol
M
ER
IT
-
H
F
tr
ia
l
39
91
0.
66
(0
.5
3–
0.
81
,P
=
0.
00
62
)
0.
65
(N
/A
)
M
ER
IT
-H
F
St
ud
y
G
ro
up
,1
9
99
C
ar
ve
d
ilo
l
C
O
PE
RN
IC
U
S
tr
ia
l
22
89
0.
65
(0
.5
2–
0.
81
,P
=
0.
00
01
3)
0.
72
(N
/A
,P
=
0.
00
01
)
Pa
ck
er
et
al
.,
20
02
N
eb
iv
ol
ol
SE
N
IO
RS
tr
ia
l
21
28
0.
88
(0
.7
1–
1.
08
,P
=
0.
21
)
0.
86
(0
.7
4–
0.
99
,P
=
0.
03
9)
ǂ
Fl
at
he
r
et
al
.,
20
05
H
yd
ra
la
zi
n
e
an
d
is
os
or
b
id
e
di
ni
tr
at
e
H
yd
ra
la
zi
n
e
an
d
IS
D
N
V-
H
eF
T
I
64
2
0.
66
(0
.4
6–
0.
96
,P
<
0.
02
8)
N
/A
C
oh
n
et
al
.,
19
86
A
-H
eF
T
10
50
0.
57
(N
/A
,P
=
0.
01
)
0.
77
(N
/A
,P
=
0.
00
1)
Ta
yl
or
et
al
.,
20
04
C
ar
d
ia
c
gl
yc
os
id
es
D
ig
ox
in
D
ig
it
al
is
In
ve
st
ig
at
io
n
G
ro
up
tr
ia
l
68
00
0.
99
(0
.9
1–
1.
07
,P
=
0.
80
)
0.
72
(0
.6
6–
0.
79
,P
<
0.
00
1)
Th
e
D
ig
it
al
is
In
ve
st
ig
at
io
n
G
ro
up
,1
9
97
Iv
ab
ra
di
ne
Iv
ab
ra
di
ne
Th
e
BE
A
U
TI
FU
L
tr
ia
l
10
91
7
1·
04
(0
·9
2–
1·
16
,P
=
0.
55
)
0·
99
(0
·8
6–
1·
13
,P
=
0.
85
)
Fo
x
et
al
.,
20
08
Th
e
SH
IF
T
tr
ia
l
65
58
0·
90
(0
·8
0–
1·
02
,P
=
0.
09
2)
0.
74
(0
.6
6–
0.
83
,P
<
0.
00
01
)
Sw
ed
be
rg
et
al
.,
20
10
A
IR
E,
th
e
A
cu
te
In
fa
rc
ti
on
Ra
m
ip
ri
lE
fﬁ
ca
cy
;C
O
N
C
EN
SU
S,
th
e
C
o
op
er
at
iv
e
N
or
th
Sc
an
d
in
av
ia
n
En
al
ap
ri
lS
u
rv
iv
al
St
ud
y;
EM
PH
A
SI
S-
H
F,
th
e
Ep
le
re
n
on
e
in
M
ild
Pa
tie
nt
sH
os
pi
ta
liz
at
io
n
an
d
Su
rv
iv
al
St
ud
y
in
H
ea
rt
Fa
ilu
re
;H
Fr
EF
,H
ea
rt
Fa
ilu
re
w
it
h
Re
d
uc
ed
Ej
ec
ti
on
Fr
ac
tio
n;
N
/A
,N
ot
A
va
ila
bl
e;
RA
LE
S,
Ra
nd
om
iz
ed
A
ld
ac
to
ne
Ev
al
ua
ti
on
St
ud
y;
SA
VE
,S
ur
vi
va
la
n
d
Ve
nt
ri
cu
la
rE
nl
ar
g
em
en
t;
SO
LV
D
,S
tu
di
es
of
Le
ft
Ve
nt
ri
cu
la
r
D
ys
fu
nc
ti
on
;V
A
LI
A
N
T,
Va
ls
ar
ta
n
in
A
cu
te
M
yo
ca
rd
ia
lI
nf
ar
ct
io
n;
Va
l-H
eF
T,
Va
ls
ar
ta
n
H
ea
rt
Fa
ilu
re
Tr
ia
l.
ǂ
In
cl
ud
es
d
ea
th
an
d
ho
sp
it
al
iz
at
io
n
.
* C
on
ﬁ
d
en
ce
in
te
rv
al
of
97
.5
%
.
§
C
o
n
ﬁ
de
nc
e
in
te
rv
al
of
98
%
¥
C
o
m
p
ar
ed
w
it
h
th
e
C
ap
to
p
ri
lt
re
at
m
en
t
gr
ou
p
.
BJP B L Loudon et al.
1914 British Journal of Pharmacology (2016) 173 1911–1924
Pharmacotherapies in heart failure BJPwasting bradykinin (Brown and Vaughan, 1998). It is now
recognized that RAAS activation incorporates a tissue compo-
nent (particularly cardiac, vascular and renal) that is indepen-
dent from the systemic endocrine effects (Dzau and Re,
1994). In the compensated state of HF, plasma renin and
ACE levels have been shown to fall in a trend towards normal
(Dzau and Hirsch, 1990). Despite this trend, elevations in tis-
sue RAAS persist, indicating its critical importance in cardio-
vascular disease states. Components of the RAAS at a tissue
level act in a paracrine or autocrine manner to produce many
tissue-speciﬁc effects, including increased vascular tone and
cardiac remodelling and ﬁbrosis (Paul et al., 2006). Indeed,
amelioration of chronic tissue RAAS activation is probably
more important in the long-term beneﬁts of neurohormonal
blockade than the haemodynamic effects of systemic RAAS
blockade (Dzau and Hirsch, 1990).
Several inﬂuential RCTs investigating ACE inhibitors in
HFrEF demonstrated reductions in mortality in the enalapril
treatment groups compared with placebo of up to 31%
(P = 0.001) (The CONSENSUS Trial Study Group, 1987; The
SOLVD Investigators, 1992). Similar mortality beneﬁts were
later demonstrated for captopril and ramipril in the Survival
And Ventricular Enlargement Trial and The Acute Infarction
Ramipril Efﬁcacy Study trials in 1992 and 1993, respectively
(Pfeffer et al., 1992; The AIRE Study Group, 1993). In 1992,
the Studies of Left Ventricular Dysfunction Prevention trial
further demonstrated reduced HF incidence and cardiovascu-
lar mortality with enalapril, in patients with asymptomatic
HFrEF (Cleland et al., 2006).
Angiotensin receptor blockers
Angiotensin receptor blockers have similar therapeutic applica-
tions to ACE inhibitors in the setting of HF. They are useful as a
monotherapy, provide an alternative option for individuals
who are intolerant of ACE inhibitors (due to cough or
angioedema) and may offer an augmented clinical effect in
combination with ACE inhibitors (likely from amore extensive
blockade of the RAAS axis). By competitively inhibiting angio-
tensin II at the angiotensin II type 1 (AT1) receptor directly,
ARBs do not cause an elevation in bradykinin nor the
attendant side effect proﬁle. The most compelling data for
ARBs versus placebowas presented by theCandesartan inHeart
Failure - Assessment of Mortality and Morbidity (CHARM) Pro-
gram trials, the Valsartan Heart Failure Trial in 2001 and the
Valsartan in Acute Myocardial Infarction trial in 2003. The
CHARM Program trials demonstrated a signiﬁcant reduction
in cardiovascular death or hospital admission for HF in the
candesartan group compared with placebo of 30% (95% CI
19–40%; P< 0.0001) in 2028 patients with symptomatic HFrEF
who were not receiving ACE inhibitors due to previous intoler-
ance (Granger et al., 2003; McMurray et al., 2003). The
Valsartan Heart Failure Trial demonstrated a 24% (13.8% vs.
18.2%, P < 0.001) reduction in hospitalizations for worsening
HF in the treatment group compared with placebo. However,
93% of study patients were also treated with ACE inhibitors,
which is probably responsible for the lack of observed effect
on mortality (Cohn and Tognoni, 2001). The Valsartan in
Acute Myocardial Infarction trial was a three-arm RCT of
14 808 patients comparing titrated valsartan, captopril and
valsartan/captopril combination therapy in patients within
0.5–10 days of an acute myocardial infarction complicated byHFrEF and demonstrated non-inferiority of valsartan to capto-
pril (Pfeffer et al., 2003).
Mineralocorticoid receptor antagonists
Direct blockade of aldosterone at the distal nephron pro-
motes ﬂuid loss and retention of potassium ions (otherwise
lost as a result of the action of loop diuretics) and further ame-
lioration of systemic and chronic tissue RAAS activation. The
two main trials to investigate the role of aldosterone
antagonists in patients with HFrEF were the Randomized
Aldactone Evaluation Study 1996 and the Eplerenone inMild
Patients Hospitalization and Survival Study in Heart Failure
2011 studies. These RCTs compared spironolactone versus
placebo in 1663 NYHA III–IV patients and eplerenone versus
placebo in 2737 NYHA II patients, respectively on standard
medical therapy. They demonstrated a 30% reduction in mor-
tality in the spironolactone arm versus placebo at 24 months
(95%CI 18–40%; P < 0.001) (Pitt et al., 1999) and a risk
reduction of 37% in composite cardiovascular death and
hospitalization for HF in the eplerenone group versus placebo
at 21 months (95%CI 26–46%; P < 0.001) (Zannad et al.,
2011) respectively. A further analysis of 261 patients from the
Randomized Aldactone Evaluation Study revealed that high
baseline levels of biomarkers of cardiac ﬁbrosis (secondary to
higher tissue RAAS activity) correlated with poorer prognosis,
and the observed beneﬁt from spironolactone was greater in
such patients (Zannad et al., 2000).
β-blockers
Sympathetic neural activation in cardiac failure is a key
compensatory mechanism to counteract falling cardiac output
and end-organ hypoperfusion. Chronically, however, elevated
catecholamines are deleterious, with pro-arrhythmogenic
effects [with the attendant decrease in coronary blood ﬂow
and increased myocardial O2 demand (Rona, 1985)] and direct
cardiotoxic effects via cAMP-mediated calcium overload,
particularly inﬂux through the verapamil-sensitive calcium
channel, which is pro-apoptotic (Mann et al., 1992). These
effects are ameliorated by β-Adrenoceptors antagonists, a
heterogeneous group of pharmacotherapeutic agents. These
agents vary greatly in their selectivity for the adrenoceptor
subtypes and may possess ancillary properties (e.g. the
antioxidant and anti-inﬂammatory properties of carvedilol
that are theoretically of great importance in HF); however,
their impact on mortality appears to be a class-wide effect
(Chatterjee et al., 2013).
The four cornerstone trials assessing β-blockers in HF
were the The Cardiac Insufﬁciency Bisoprolol Study II
(CIBIS-II; 1999), Metoprolol cr/xl Randomized Intervention
Trial in Congestive Heart Failure (MERIT-HF; 1999),
Carvedilol Prospective Randomized Cumulative Survival
Study (COPERNICUS; 2002) and the Study of the Effects of
Nebivolol Intervention on Outcomes and Rehospitalization
in Seniors with heart failure (SENIORS; 2005) studies. The
MERIT-HF and CIBIS-II trials in 1991 assessed controlled
release metoprolol versus placebo in 3991 HFrEF patients
and bisoprolol versus placebo in 2647 HFrEF patients,
respectively (MERIT-HF; The CIBIS-II Study Group, 1999).
Both trials demonstrated an impressive 34% reduction in
mortality (95% CI 19–46%, P < 0.0001 and 95% CI
19–47%, P = 0.0062 respectively) in the treatment armBritish Journal of Pharmacology (2016) 173 1911–1924 1915
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carvedilol versus placebo in 2289 patients with severe HF
and LVEF ≤25% and demonstrated a 35% (95% CI 19–48%,
P = 0.0014) reduction in mortality in the treatment group
compared with placebo (Packer et al., 2002). A signiﬁcant
mortality beneﬁt in 2128 patients >70 years of age was
shown in the SENIORS trial in 2005, the ﬁrst trial to speciﬁ-
cally target HFrEF patients of advanced age. In the nebivolol
treatment arm compared with placebo, there was a reduction
in the composite primary outcome of all-cause mortality and
cardiovascular hospitalizations of 14% (95%CI 1–26%,
P = 0.039) (Flather et al., 2005). This improvement in the
composite outcome was driven mainly by a reduction in
cardiovascular hospitalizations, with no effect on all-cause
mortality.
Diuretics
The careful balance between ﬂuid retention following
chronic neurohormonal activation and compensatory
natriuretic mechanisms is precarious and may be affected
by the slightest changes in homeostasis. Fluid overload
causes pulmonary congestion (in left heart failure) and
gastrointestinal, hepatic and peripheral congestion (in right
heart failure). This leads to the often debilitating and
unacceptable symptomatology of the HF syndrome. Indeed,
the evidence for the use of diuretics in HF is geared for the
treatment of these symptoms and is experience-based, with
a paucity of robust clinical data in relation to improvements
in disease mortality (Faris et al., 2002). Loop diuretics are the
most efﬁcacious and potent in alleviating symptoms, both
in acute decompensation and chronic disease, but as with
all diuretics, they must be carefully titrated against
hypokalaemia (excluding potassium sparing), symptomatic
hypotension and renal decline (a signiﬁcant cause of
mortality in patients who die from worsening HF (Sarraf
et al., 2009).
Hydralazine and isosorbide dinitrate
The effect of reducing both resistance vessel and venous
tone on the failing heart via the simultaneous use of the
arterial vasodilator hydralazine and the arteriolar and
venodilator isosorbide dinitrate (ISDN) was assessed in the
Vasodilator Heart Failure trials (V-HeFT I/II) and the
African-American Heart Failure Trial in 1986, 1991 and
2004 respectively. The V-HeFT I trial compared hydralazine
and ISDN versus prazosin with placebo in 642 men with
impaired systolic function and demonstrated a 34% relative
risk reduction at 2 years (P < 0.028) (Cohn et al., 1986). V-
HeFT II was undertaken in 1991 to compare this combina-
tion with and without enalapril, with signiﬁcant mortality
beneﬁt seen in the enalapril arm (Cohn et al., 1991). Hydral-
azine and ISDN in combination was also shown to reduce ni-
trate tolerance by previously unknown mechanisms. Organic
nitrates activate NADPH oxidase, which results in deleterious
ROS generation, partially contributing to nitrate tolerance via
endothelial dysfunction (uncoupling of NOS) and inhibition
of mitochondrial aldehyde dehydrogenase 2 (responsible for
a large part of organic nitrate enzymatic bioactivation to
NO) (Munzel et al., 2005). It seems fortuitous that hydral-
azine was used in addition to organic nitrates, as evidence
later emerged that it prevents NADPH oxidase activation,1916 British Journal of Pharmacology (2016) 173 1911–1924reducing nitrate toxicity, tolerance and free radical produc-
tion (Munzel et al., 1996). Given the mortality beneﬁt, hy-
dralazine and ISDN may provide a reasonable alternative to
ACE inhibitors in patients who cannot tolerate ACE
inhibitors or ARBs. More speciﬁcally, African-American
populations, in whom low-renin, volume-expansive hyper-
tension is a common comorbid cardiovascular condition
(Cook, 1988), the use of augmenters of ACE-inhibitor action
is encouraged to reduce the very high doses of ACE inhibi-
tors otherwise required. The African-American Heart Failure
Trial randomly assigned 1050 Black patients with NYHA
III/IV HF on standard medical therapy (including ACE in-
hibitors) to hydralazine and ISDN versus placebo. There
was a signiﬁcant decrease in all-cause mortality in the treat-
ment arm (P = 0.02) at 3 years (Taylor et al., 2004). Despite
the compelling data for the use of organic nitrates in HFrEF,
the use of nitrates in HFpEF has been relatively untested
until recently, with many clinicians prescribing them to
increase exercise tolerance and activity levels. The Nitrate’s
Effect on Activity Tolerance in Heart Failure trial, a
multicentre, double-blind crossover study of isosorbide
mononitrate in HFpEF, demonstrated that, in fact, patients
in the treatment arm trended towards being less active and
had no beneﬁcial increase in exercise capacity compared
with placebo (Redﬁeld et al., 2015).
Cardiac glycosides
Positive inotropic effects combined with vagally mediated
negatively chronotropic effects present a favourable proﬁle
for the use of cardiac glycosides. Outside of their use in
managing tachyarrhythmias however, there has been no
convincing effect on cardiovascular mortality in HF
demonstrated. The role of digoxin in HF remained heatedly
controversial given the risks for toxicity, despite over 200-
years of clinical experience, until more recently, and the
argument has been left largely unresolved. The largest study
to look at the use of digoxin in HF patients was the Digitalis
Investigation Group trial in 1997. This multicentre double-
blind trial assessed digoxin versus placebo in 6800 patients
with a LVEF ≤45% on conventional medical therapy
including diuretics and ACE inhibitors. All-cause mortality
was not signiﬁcantly affected; however, fewer patients were
hospitalized for worsening HF with a risk reduction of 28%
(95% CI 21–34%, P < 0.001) (The Digitalis Investigation
Group, 1997). A post hoc analysis of the Digitalis Investigation
Group trial demonstrated a correlation between serum
digoxin concentrations and crude all-cause mortality, with
signiﬁcantly higher mortality in the toxic range and no
beneﬁt outside of the target range of 0.5 to 0.8 ngmL1
(Rathore et al., 2003), stressing the importance of regular
plasma monitoring. A randomized, placebo-controlled trial
investigating the addition of digoxin to conventional ther-
apy is ongoing (EudraCT:2007-006660-30).
Ivabradine
A resting heart rate ≥70 bpm in patients with HFrEF has been
shown to have a negative impact on cardiovascular outcomes
(Fox et al., 2008). Ivabradine is a selective If current inhibitor
in the sinoatrial node, causing exclusively negative chro-
notropic effects. Ivabradine has therefore also found a role
in the clinical setting for patients in whom β-blockade is not
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evaluation of the If inhibitor ivabradine in patients with
coronary disease and left ventricular dysfunction trial (BEAU-
TIFUL; 2008) and systolic heart failure treatment with the If
inhibitor ivabradine trial (SHIFT; 2010) studies were pivotal
trials underpinning the evidence for ivabradine in HF. The
BEAUTIFUL trial assessed 10 917 HFrEF patients with stable
coronary artery disease and a resting heart rate ≥60 bpm in
sinus rhythm despite maximally tolerated β-blockade. This
trial failed to demonstrate a reduction in mortality, but
suggested a trend towards beneﬁt in patients with resting
HR ≥70 bpm (Fox et al., 2008). In 2010, The SHIFT trial
randomized 6558 patients with HFrEF who were in sinus
rhythm with HR ≥70 bpm and had been admitted to hospital
for HF within the previous year to receive ivabradine or
placebo. Ivabradine reduced both the risk of death due to
HF compared with placebo and hospital admissions for
worsening HF by 26% (P < 0.0001) (Swedberg et al., 2010).
These promising data have been challenged however, as
despite 90% of patients receiving β-blockers, only 26% of
patients were successfully titrated to full doses, and up to
40% of patients were not managed with a mineralocorticoid
receptor antagonist, suggesting sub-optimal concomitant
conventional medical therapy (Teerlink, 2010). Indeed, in a
recent and much larger study of 19 102 patients with stable
coronary artery disease without clinical evidence of HF,
targeted heart rate reduction to a mean of 61 bpm conferred
no demonstrable beneﬁt in the treatment arm, and in fact, a
conﬂicting increase was observed in the composite primary
endpoint of cardiovascular death and non-fatal acute myo-
cardial infarction in patients with severe activity-limiting
angina (Fox et al., 2014). The debate on the role of ivabradine
in cardiovascular disease is therefore ongoing.Neprilysin inhibition
Heart failure stimulates the compensatory natriuretic pep-
tide system, which is composed of atrial natriuretic peptide,
brain natriuretic peptide (BNP), C-type natriuretic peptide
and other vasoactive substances such as angiotensin II and
bradykinin (Vardeny et al., 2014). Neprilysin degrades these
vasoactive peptides, and so targeted inhibitors of neprilysin
increase circulating levels of these substances and counter-
act the effects of neurohormonal over-activation. Sole
inhibitors of neprilysin, however, failed to demonstrate a
signiﬁcant impact on blood pressure in hypertensive co-
horts and so were discontinued (McDowell and Nicholls,
1999). This may have been in part due to an attendant
increase in angiotensin, necessitating the combination of
neprilysin inhibitors with drugs that target the RAAS.
Omapatrilat, the ﬁrst dual neprilysin and ACE inhibitor,
was shown to be superior to enalapril alone (Kostis et al.,
2004). Unfortunately, there was a signiﬁcant increase in
the incidence of angioedema in the treatment arm (likely
to be due to the substantial inhibition of bradykinin degra-
dation), and the drug was discontinued. LCZ696, a combi-
nation of sacubitril (neprilysin inhibitor) and valsartan
(ARB), as previously stated, showed a similar reduction in
all-cause mortality compared with an ACE inhibitor combi-
nation, with better safety data due to an attenuated effect
on bradykinin breakdown (Packer et al., 2015).Metabolic dysfunction in heart failure
Normal cardiac metabolism
The continuous and coordinated contractile activity of cardiac
myocytes requires the consumption of vast amounts of energy,
and this is reﬂected in the observation of tremendous
mitochondrial density on histology (Goffart et al., 2004). Fatty
acid (FA) metabolism predominates in adult healthy cardiac
myocytes (around 70%), which is complemented by carbohy-
drate oxidation (20%) and, to a lesser extent, contribution from
ketones and various amino acids (Stanley et al., 2005). However,
the healthy heart is a metabolic ‘omnivore’, which is able to
adjust substrate utilization according to substrate availability
(Singh et al., 2014). Glucose enters themyocyte through glucose
transporters (predominantly GLUT4). Glucose also undergoes a
series of metabolic conversions in the cytosol known as glycoly-
sis, resulting in the production of pyruvate, which is actively
transported across the mitochondrial membrane where the
pyruvate dehydrogenase (PDH) enzyme complex catalyses its
conversion to acetyl CoA. PDH is the rate-limiting step in
carbohydratemetabolism and is negatively regulated by kinases
and positively regulated by phosphatases (Doenst et al., 2013).
Hypoxia potently inhibits PDH; therefore in these circum-
stances pyruvate is converted to lactate (anaerobic glycolysis).
PDH is also subject to marked allosteric regulation, with acetyl
CoA and NAD+ inhibiting PDH via kinase activation.
Long-chain fatty acids enter the myocyte via fatty acid
transporters and undergo esteriﬁcation to long-chain fatty
acyl CoA. These are actively transported into the mitochon-
dria via the ‘carnitine shuttle’ (van der Vusse et al., 2000).
The enzyme carnitine palmitoyltransferase type 1 (CPT1)
catalyses the addition of a carnitine group to the fatty acyl
CoA molecule, facilitating transfer across the mitochondrial
membrane where the enzyme CPT2 cleaves the carnitine
(which is exported back across the mitochondrial mem-
brane). In the mitochondria, the fatty acyl CoA undergoes β-
oxidation, a four-step process generating acetyl CoA, NADH
and ﬂavin adenine dinucleotide (FADH2). Acetyl CoA arising
from both fuel sources enters the tricarboxylic acid (TCA)
cycle to produce NADH (Schwarz et al., 2014). High-energy
electrons donated from NADH and FADH2 (derived from suc-
cinate dehydrogenase, another component of the TCA cycle)
are transferred from complex to complex of the electron
transport chain to power extrusion of hydrogen ions across
the membrane to generate an electrochemical gradient. This
ultimately powers phosphorylation of ADP to ATP by ATP
synthase within the mitochondrial inner membrane, with
oxidation of the hydrogen ions to water (Figure 2). ATP
within the mitochondria donates high-energy phosphate to
creatine catalysed by mitochondrial creatine kinase (CK),
which is transported to the sites of energy utilization within
the cytosol (Neubauer, 2007). Here, phosphocreatine (PCr)
phosphorylates ADP to ATP (catalysed by cytosolic CK) to
power the multitude of myocardial sarcomeres and various
ion channels.
The high-energy nature of the electrons utilized in oxidative
phosphorylation results in the formation of harmful reactive
oxygen species (ROS) (Schwarz et al., 2014), even in physiologi-
cal states. Complex homeostatic mechanisms, including
NADPH from the pentose phosphate pathway (PPP), exist to
manage low levels of ROS and protect cardiac myocytes fromBritish Journal of Pharmacology (2016) 173 1911–1924 1917
Figure 2
Schematic of the key metabolic pathways in cardiac myocytes. Fatty acid and glucose metabolism are key metabolic pathways within cardiac
myocytes that are responsible for generating large amounts of ATP. Perhexiline and nitrite are therapeutic agents that have the ability to modulate
and enhance cardiac metabolism. Acetyl CoA, acetyl coenzyme A; ADP, adenosine diphosphate; ATP, adenosine triphosphate; CPT, carnitine
palmitoyltransferase; ETC, electron transport chain; FADH2, ﬂavin adenine dinucleotide; NADH, nicotine adenine dinucleotide; Pi, inorganic
phosphate; TCA, tricarboxylic acid.
BJP B L Loudon et al.detrimental mitochondrial DNA damage and subsequent
activation of apoptotic pathways. Uncoupling proteins [both
uncoupling protein (UCP) and adenine nucleotide translocase
(ANT)] facilitate proton leak back into the mitochondria
resulting in reduced ROS generation but also less ATP produc-
tion. The activity of UCPs and ANT are increased by ROS
(Schwarz et al., 2014).
Metabolic changes in heart failure
Given the high-energy consumption within the normal
heart, it is appropriate to deﬁne HF as a condition in which
metabolic impairment is a predominant feature. A decrease
in ATP production (with resultant energetic starvation)
resulting from impaired generation from glucose and FA and
activation of energy-consuming biosynthetic and redox-
stress pathways are mechanisms by which this metabolic
shift occurs (Doenst et al., 2013). Creatine delivery and CK
activity and ﬂux are also reduced in HF (impairing ATP
delivery to sarcomeres and ion channels necessary for pump
function and cardiac homeostasis), which causes a reduction
in the energy charge within the cytosol, as reduced delivery of
ATP reduces the phosphorylation potential of ADP (given by
Gibbs Law [ATP]/[ADP] [Pi]) (Siddiqi et al., 2013). These com-
plex changes in the HF population are inconsistent across the
aetiologies of HF, however, they becomemore uniform across
groups at the onset of systolic dysfunction. A mechanistic
study of 14 patients with aortic stenosis demonstrated a
reduced PCr to ATP ratio on magnetic resonance spectros-
copy in patients with symptoms of HF compared with those
without (1.1 vs. 1.56, P < 0.0035) (Conway et al., 1991). PCr1918 British Journal of Pharmacology (2016) 173 1911–1924to ATP ratio has been well validated as a marker of cardiac
metabolic status and efﬁciency (Beadle and Frenneaux, 2010).
The reduction in ATP production in HF is complex. Cat-
echolaminergic stimulation in HF results in activation of li-
polytic pathways and an increase in plasma-free FAs. As a
result, FA accumulation occurs within cardiac myocytes
and mitochondria. Down-regulation of enzymes for β-
oxidation occurs due to a decrease in activity of the PPARα
pathway, which is a transcriptional regulator of FA use
(Doenst et al., 2013). Decreased FA uptake and oxidation
(with preferential utilization of carbohydrates) have been
observed in patients with dilated cardiomyopathy and
symptoms of HF compared with healthy controls (Neglia
et al., 2007). In a further molecular study analysing human
left ventricular biopsy tissue, total expression and mRNA
levels of medium-chain and long-chain acyl CoA dehydro-
genase (involved in FA β-oxidation) were down-regulated
by >40% (P < 0.05) in patients with HF compared with
age-matched controls (Sack et al., 1996). A ‘funnelling’ effect
occurs due to reduced β-oxidation and increased mitochon-
drial FA in HF, and FAs begin to react with ROS within
mitochondria to form lipid peroxides. Lipid peroxides
damage mitochondrial DNA (hence impairing their ATP-
production capacity) and other cellular structures and
activate MAPK pathways, triggering adverse remodelling
and ﬁbrosis (Siddiqi et al., 2013). Lipid peroxides also in-
crease the activation of UCPs and ANT on the mitochondrial
membrane, a protective mechanism allowing the mitochon-
drion to transport them back into the cytosol (Schrauwen
and Hesselink, 2004). Unfortunately, this allows for proton
Pharmacotherapies in heart failure BJPleak at the electron transport chain and reduces the efﬁciency of
ATP production.
Glucose oxidation is also impaired in patients with HFrEF.
There is profound cardiac insulin resistance in HF, with
decreased insulin-dependent glucose uptake, but normal or
increased insulin-independent glucose uptake. G6P (formed by
phosphorylation of glucose on entry into the cardiac myocyte)
is also shunted downothermetabolic pathways that do not pro-
duce ATP (Doenst et al., 2013). The hexosamine biosynthesis
pathway, a growth and protein synthesis pathway, is increased
in HF and contributes to cardiac hypertrophy and remodelling.
The PPP is also up-regulated to produce increased levels of
NADPH, which are required for anti-oxidative defence at low
levels of ROS (Burgoyne et al., 2012), but may contribute to ox-
idative stress when ROS levels are high. G6P will also enter the
glycolytic pathway to produce pyruvate. InHF, there is impaired
oxidation of pyruvate to acetyl CoA by the PDH complex,
reducing the amount available for entry into the TCA cycle. A
high-salt diet-induced HF model in rats demonstrated a reduc-
tion in GLUT1 and PDH expression (Kato et al., 2010), and this
was replicated in an in vivo thoracic aortic constriction HF
murine model (Dai et al., 2013). PDH activity also appears to
be reduced in HF resulting in impaired carbohydrate oxidation
despite the availability of pyruvate (Singh et al., 2014). Pyruvate
levels available for oxidation are also reduced in HF, as it is
shunted along anaplerotic pathways (without ATP production)
to replenish amino acids within the TCA cycle that have been
utilized in hypertrophic growth and remodelling. The
anaplerosis of pyruvate is enhanced in the presence of NADPH
(derived from the up-regulated PPP) and may consume large
amounts of NADPH and impair anti-oxidative defence (Doenst
et al., 2013). The changes in cardiac metabolism culminate in
hypertrophy and ﬁbrosis reduced availability of ATP and high
ROS levels, which further worsen the structural changes and
energetic starvation.
Metabolic modulators
Glucose metabolism is more efﬁcient than FA metabolism (in
terms of oxygen requirement), and therefore, shifting energy
production towards this system (generally through direct or
indirect PDH complex activation) in patients with cardiovascu-
lar disease has been suggested in order to correct metabolic
impairment and reduce ROS production (Lopaschuk et al.,
2002). Various metabolic modulators exist, including perhe-
xiline, trimetazidine, ranolazine and etomoxir. Of these agents,
perhexiline has shown great promise due to its high potency
and well-documented anti-ischaemic properties (Horowitz and
Chirkov, 2010).
Perhexiline was widely used throughout the 1970s for the
treatment of refractory angina pectoris (Ashraﬁan et al.,
2007). It was later revealed that perhexiline improved cardiac
function andmyocardial efﬁciency by down-regulating CPT1
activity, the rate-limiting enzyme required for transport of
FAs across the mitochondrial membrane (Kennedy et al.,
1996). This in turn prevents mitochondrial FA build up,
limiting harmful ROS production and subsequent energetic
impairment. Recently, it has also been proposed that
perhexiline may directly increase activity of the PDH com-
plex (Yin et al., 2013). This improved glucose metabolism at
low oxygen tensions improves metabolic efﬁciency and,
when used at earlier stages of cardiovascular disease, mayslow progression. Despite these promising ﬁndings, the use
of perhexiline drastically declined during the 1980s due to
several adverse effects. These ranged from minor nausea and
lethargy to debilitating peripheral neuropathy and hepato-
toxicity (Shah et al., 1982). Severe toxicity, however, results
from direct inhibition of liver and brain isoforms of the
CPT1 enzyme, which may be avoided by tightly monitoring
plasma concentrations within a target therapeutic range of
0.5–2.2 μM (Horowitz et al., 1986).
In a cohort study involving elderly patients aged >75 years
with inoperable aortic stenosis, treatment with perhexiline
improved NYHA functional class (P < 0.01), with an 80% 12-
month actuarial survival rate (Unger et al., 1997). In an RCT
performed by our group involving 46 patients with hypertro-
phic cardiomyopathy treated with perhexiline or placebo for a
mean of 4.6 months, improved cardiac energetics were demon-
strated by improved PCr/ATP ratio (1.27 to 1.73, P = 0.03) and
NYHA class (P < 0.001) in the perhexiline arm (Abozguia et al.,
2010). A further RCT by us focusing on patients with HFrEF
has also shown signiﬁcant improvements in peak exercise
oxygen consumption (16.1 ± 0.6 vs. 18.8 ± 1.1 mLkg1min1,
P < 0.001) and LVEF (24% vs. 34%, P < 0.001) following treat-
ment with perhexiline (Lee et al., 2005).
Trimetazidine is a weak CPT1 inhibitor (Kennedy and
Horowitz, 1998) with potent inhibitory effects on the long-
chain 3-ketoacyl-CoA thiolase enzyme, which is involved in
the ﬁnal steps of FA β-oxidation (Kantor et al., 2000). Simi-
larly to perhexiline, trimetazidine is an effective antianginal
and has been shown to increase time to exercise tolerance
in combination with metoprolol (420 ± 108 s in the placebo
group to 485 ± 122 s in the treatment arm, P < 0.05) in
patients with chronic stable angina (Trimetazidine in Poland
II study trial) (Szwed et al., 2001). Trimetazidine was further
shown to improve left ventricular end-systolic volume
(98 ± 1.36 mL vs. 81 ± 27 mL, P = 0.04), with a corresponding
increase in ejection fraction (36 ± 7% vs. 43 ± 10%, P = 0.002)
(Fragasso et al., 2006).
Ranolazine has also been found to have antianginal effects
and holds a similar chemical structure to trimetazidine
(Horowitz and Chirkov, 2010). The exact mechanism of action
remains unknown; however, in a global ischaemia rat model,
ranolazine was found to partially inhibit FA oxidation and stim-
ulate glucose oxidation (McCormack et al., 1996). These meta-
bolic changes were shown to have therapeutic effects in a
three-group (placebo vs. one of two doses of ranolazine), paral-
lel, double-blind placebo-controlled trial involving 823 chronic
stable angina sufferers on background antianginal therapy
(Combination Assessment of Ranolazine in Stable Angina
Study trial). The treatment groups experienced an increased
time to angina on exercise and could exercise for longer
compared with the placebo arm (Chaitman et al., 2004). Nitro-
glycerin use also decreased in the treatment arm by one use per
week vs. placebo (P< 0.02). In a recent, small proof-of-concept
RCT, ranolazine was further shown to improve
haemodynamics [with decreases in left ventricular end-
diastolic pressure (P = 0.04) and pulmonary capillary wedge
pressure (P = 0.04) in patients with HFpEF (Maier et al., 2013)].
Etomoxir also inhibits the CPT1 enzyme, although to a
lesser extent than perhexiline (Luiken et al., 2009). In a
failing rat-heart model, perfusion with etomoxir improved
left ventricular haemodynamics and indices of myocardialBritish Journal of Pharmacology (2016) 173 1911–1924 1919
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ﬁrst-in-human study of etomoxir in 10 HF patients of non-
ischaemic origin demonstrated haemodynamic improve-
ment in HFrEF, with an increase in LVEF (21.5 ± 2.6% to
27.0 ± 2.3%, P< 0.01) and exercise cardiac output (from 9.72-
± 1.25 Lmin1 to 13.44 ± 1.50 Lmin1, P < 0.01) (Schmidt-
Schweda and Holubarsch, 2000). The long-term safety of
etomoxir, however, has been questioned due to a recent clin-
ical trial involving 260 patients with moderate HF, which was
halted early due to four patients developing signiﬁcant he-
patic transaminitis (Holubarsch et al., 2007).A novel therapeutic pathway:
nitrate–nitrite–NO
The nitrate–nitrite–NO pathway has been suggested as an
alternative mechanism for systemic NO production. This is
an alternative mechanism to the classical pathway in which
NO is produced by oxidation of L-arginine in a reaction
catalysed by nitric oxide synthase (NOS) (Lundberg et al.,
2008). NO generated through the nitrate–nitrite–NO pathway
has been suggested to involve a series of nitric oxide synthase
(NOS)-independent and oxygen-independent reactions. How-
ever, the precise mechanism(s) for nitrite conversion to NO re-
mains to be fully elucidated because a number of enzymes
have been implicated in the catalysis of nitrite to NO in various
tissue compartments (Lundberg et al., 2008). Green leafy vegeta-
bles (such as spinach and beetroot) are the major source of die-
tary inorganic nitrate. Once consumed, the salivary inorganic
nitrate is reduced to nitrite by commensal bacteria. Nitrite is
then swallowed, absorbed from the stomach and reduced to
NO, particularly under hypoxic conditions, by a number of ni-
trite reductases such as myoglobin, haemoglobin and
xanthine oxidoreductase (Gladwin and Kim-Shapiro, 2008;
Webb et al., 2008). NO may then directly modify proteins
[particularly via S-nitrosylation of cysteine residues, which
may enhance or dampen protein activity (Foster et al.,
2003)] or, more classically, activate soluble guanylate cyclase
within vascular smooth muscle cells and platelets to increase
cGMP to exert its vasodilator and platelet-inhibitory effects.
Phosphodiesterase is pivotal in homeostatic control over
cellular cGMP and cAMP activity; thus, targeted inhibition of
cardiac and smoothmuscle isoforms of phosphodiesterase have
been shown to elicit vasodilatation and attenuate cardiac hyper-
trophy (Guazzi, 2008). A placebo-controlled RCT involving 23
stable HF patients treated with the PDE5 inhibitor sildenaﬁl
for 6 months demonstrated an improvement in pulmonary
artery systolic pressure (33.7 to 23.9 mmHg, P < 0.01) and
aerobic efﬁciency and exercise ventilation (peak VO2 14.8 to
18.7 mLmin1kg1, P < 0.01) (Guazzi et al., 2007). These
promising data are yet to be explored in larger clinical trials.
Exploitation of the NO pathway has been further attempted
with other stimulators and activators of soluble guanylate
cyclase including riociguat, vericiguat and cinaciguat. Recently,
the Soluble Guanylate Cyclase Stimulator in Heart Failure Study
(in patients with LVEF <45%) trial, a randomized-controlled,
multicentre double-blind trial to assess the tolerability and
optimal dose of vericiguat in 456 patients with HFrEF,
conﬁrmed tolerability but failed to show a signiﬁcant decrease
in NT-proBNP in the treatment groups (the primary endpoint).1920 British Journal of Pharmacology (2016) 173 1911–1924There was, however, a demonstrable dose–response relationship
for the reduction in NT-proBNP (P < 0.02), which was promis-
ing and requires further elucidation (Gheorghiade et al., 2015).
The nitrate–nitrite–NO pathway has been shown to regu-
late blood pressure and hypoxic vasodilatation and improve
exercise performance and mitochondrial efﬁciency (Bailey
et al., 2014). Our work and those of others have demonstrated
that infusions of sodium nitrite in healthy subjects dilate
forearm vasculature, with signiﬁcant potentiation during
hypoxia, thereby preferentially dilating capacitance vessels
(Maher et al., 2008; van Faassen et al., 2009; Totzeck et al.,
2012; Kapil et al., 2014). As such, these haemodynamic effects
have sparked interest in inorganic nitrate (to increase serum
nitrite) as a novel oral therapeutic intervention, particularly
in cardiovascular diseases such as HFrEF. We have recently
shown in a ﬁrst-in-human HF efﬁcacy/safety study that
sodium nitrite infusion (50 μgkg1min1) in patients with
severe HF resulted in an increase in ventricular stroke volume
(43.22 ± 21.5 to 51.84 ± 23.6mL, P = 0.003), withmarked falls
in pulmonary vascular resistance (29%; P = 0.03) and right
atrial pressure (40%; P = 0.007), but onlymodest falls inmean
arterial blood pressure (4 mm Hg; P = 0.004). The increase in
stroke volume correlated (r = 0.67; P = 0.003) with an increase
in estimated trans-septal gradient (= pulmonary capillary
wedge pressure  right atrial pressure), suggesting relief of
diastolic ventricular interaction as a contributorymechanism
(Ormerod et al., 2015).
Nitrite has also been shown to improve the metabolic
efﬁciency of skeletal muscle. This may be partially due to its
vasodilator properties, but it has also been shown to have
direct effects on key metabolic components (Clerc et al.,
2007; Basu et al., 2008). The Karolinska group showed in a
double-blind crossover trial in healthy volunteers that oral
inorganic nitrate supplementation improves oxidative phos-
phorylation efﬁciency in skeletal muscle mitochondria. An
analysis of mitochondrial function revealed decreased ex-
pression of ANT and decreased mitochondrial membrane
uncoupling (Larsen et al., 2011). It has also been proposed
that under hypoxic conditions, nitrite may act as the terminal
electron acceptor in place of oxygen (Basu et al., 2008). Given
the underlying metabolic impairment in HF and the potential
beneﬁt ofmetabolic modulation, determining whether changes
observed in skeletal muscle translates to cardiac muscle would
be of great beneﬁt, but remains yet unclear. Zamani et al.
(2015) reported in a double-blind, placebo-controlled crossover
study that nitrate rich beetroot juice (12.9 mmol) in patients
with HFpEF increased exercise cardiac output and improved
peak VO2 compared with nitrate-deplete placebo (Zamani
et al., 2015). These new studies provide evidence of promising
beneﬁcial effects in patients with HF, and phase 2 studies for
longer treatment regimens are underway (ISRCTN16356908;
NCT02256345; ACTRN12615000906550; ACTRN1261300068
9774; NCT02401126).Conclusion
Classic treatments for HF have resulted in signiﬁcant improve-
ments in disease morbidity and mortality over the last 20 years.
Despite this, cohorts of patients remain who cannot tolerate
maximal up-titration of traditional treatment modalities or
Pharmacotherapies in heart failure BJPremain symptomatic despite them. With rapid improvements
in cardiac devices, we may be entering the surgical age of HF
treatment, but such interventions remain expensive and
inaccessible to many. Novel pharmacotherapeutic agents, such
as perhexiline and nitrite, may provide pharmacological
alternatives to traditional treatments and ﬁll the therapeutic
gap, but further deﬁnitive trials are warranted.Acknowledgements
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